JAN LESCHLY, CEO of Anglo-American drugmaker SmithKline Beecham, spent 1995 digesting $5 billion in acquisitions of managed-care and consumer-medicine markets, then turned his attention to heartburn--by managing the transition of ulcer drug Tagamet, once the world's largest-selling drug, to over-the-counter. SKB's sales could hit $10 billion in '95.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE